Format

Send to

Choose Destination
Front Oncol. 2015 Aug 26;5:193. doi: 10.3389/fonc.2015.00193. eCollection 2015.

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation.

Author information

1
Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital , Columbus, OH , USA.
2
Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio , San Antonio, TX , USA.

Abstract

Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and "omics" approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.

KEYWORDS:

bioinformatics; biomarkers; copy number variation; drug efficacy; drug sensitivity; expression profiling; human tumor xenografts; preclinical pharmacology

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center